Professor Mark James McKeage



Professor Mark McKeage is a physician-scientist whose research focuses on anticancer drug development and precision medicine. He has qualifications as a medical oncology specialist (MBChB, FRACP), in postgraduate research (MMedSc, PhD) and over 25 years post-PhD research experience. He has many years experience as research group leader (Cancer Clinical Pharmacology Research Group), practising medical oncologist, clinical trial investigator, graduate student thesis supervisor, and teacher of pharmacology, oncology and clinical medicine.  In his clinical work he sees both public and private patients. He has an extensive track record of research publication in the fields of cancer clinical pharmacology, combination phase I oncology clinical trials and the pharmacology and neurotoxicity of platinum-based antitumour drugs, currently standing at 124 research articles, 4778 citations and an h-index of 38 (Web of Science). To date, these include 80 research articles as first, senior and/or corresponding author, over 50 in the field of platinum drug pharmacology and toxicology, and original reports of 15 phase I oncology clinical trials. His current research projects seeks to understand mechanisms and develop treatments for platinum drug neurotoxicity and tumour resistance, and to improve lung cancer healthcare in New Zealand via the implementation of novel genetic testing strategies for selecting patients for targeted therapy.

Professor McKeage is currently Professor in the Department of Pharmacology and Clinical Pharmacology, and Co-director of the Auckland Cancer Society Research Centre at the University of Auckland. He previously he worked at The Institute of Cancer Research and Royal Marsden Hospital (London UK) and the Prince of Wales Hospital, a teaching hospital of the University of New South Wales. 

Research | Current

Most recent research articles


Aye, PS, McKeage, MJ, Tin Tin, S, Khwaounjoo, P, Elwood, J. Mark(2021). "Population-based incidence rates and increased risk of EGFR mutated non-small cell lung cancer in Māori and Pacifica in New Zealand." PLoS One 16(5): e0251357.


Aye PS, Tin Tin S, McKeage MJ, Khwaounjoo P, Cavadino A, Elwood JM. Development and validation of a predictive model for estimating EGFR mutation probabilities in patients with non-squamous non-small cell lung cancer in New Zealand. BMC Cancer. 2020;20(1):658.

Aye PS, McKeage MJ, Tin Tin S, Khwaounjoo P, Elwood JM. Factors associated with overall survival in a population-based cohort of non- squamous NSCLC patients from northern New Zealand: A comparative analysis by EGFR mutation status. Cancer Epidemiology. 2020;69:101847.


Selected publications and creative works (Research Outputs)

As of 29 October 2020 there will be no automatic updating of 'selected publications and creative works' from Research Outputs. Please continue to keep your Research Outputs profile up to date.
  • McKeage, M. J., Tin Tin, S., Khwaounjoo, P., Sheath, K., Dixon-McIver, A., Ng, D., ... Laking, G. R. (2020). Screening for anaplastic lymphoma kinase (ALK) gene rearrangements in non-small-cell lung cancer in New Zealand. Internal medicine journal, 50 (6), 716-725. 10.1111/imj.14435
    Other University of Auckland co-authors: Sandar Tin Tin, Mark Elwood
  • Nishio, M., Felip, E., Orlov, S., Park, K., Yu, C.-J., Tsai, C.-M., ... Mok, T. (2020). Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 15 (4), 609-617. 10.1016/j.jtho.2019.11.006
  • Thi, A. M., Tin Tin, S., Mckeage, M., & Elwood, J. M. (2020). Utilisation and Determinants of Epidermal Growth Factor Receptor Mutation Testing in Patients with Non-small Cell Lung Cancer in Routine Clinical Practice: A Global Systematic Review. Targeted Oncology, online first10.1007/s11523-020-00718-w
    Other University of Auckland co-authors: Sandar Tin Tin, Mark Elwood
  • Pelosi, L., Han, C. H., & McKeage, M. J. (2020). Muscle ultrasound in the assessment of oxaliplatin-induced neurotoxicity. Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology, 131 (1), 343-344. 10.1016/j.clinph.2019.10.001
    Other University of Auckland co-authors: Catherine Han
  • Biswas, R., Bugde, P., He, J., Merien, F., Lu, J., Liu, D.-X., ... Li, Y. (2019). Transport-Mediated Oxaliplatin Resistance Associated with Endogenous Overexpression of MRP2 in Caco-2 and PANC-1 Cells. CANCERS, 11 (9)10.3390/cancers11091330
  • Cho, B. C., Obermannova, R., Bearz, A., McKeage, M., Kim, D.-W., Batra, U., ... Geater, S. L. (2019). Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 14 (7), 1255-1265. 10.1016/j.jtho.2019.03.002
  • Myint, K., Biswas, R., Li, Y., Jong, N., Jamieson, S., Liu, J., ... Lu, J. (2019). Identification of MRP2 as a targetable factor limiting oxaliplatin accumulation and response in gastrointestinal cancer. Scientific reports, 9 (1)10.1038/s41598-019-38667-8
    Other University of Auckland co-authors: Catherine Han, Stephen Jamieson, Christopher Squire
  • Tin Tin, S., McKeage, M. J., Khwaounjoo, P., Thi, A. M., & Elwood, J. M. (2018). Incomplete uptake of EGFR mutation testing and its impact on estimation of mutation prevalence in patients with non-squamous NSCLC: A population-based study in New Zealand. Cancer epidemiology, 57, 24-32. 10.1016/j.canep.2018.09.004
    Other University of Auckland co-authors: Sandar Tin Tin, Mark Elwood


Contact details

Primary office location

M&HS BUILDING 504 - Bldg 504
Level 2, Room 236A
New Zealand

Web links